Contrive Datum Insights has published "Antimicrobial Susceptibility Testing Market Size, Share & Industry Analysis, By Product type (Automated & Semi-Automated AST Instruments, Reagents & Consumables, Manual & Non-Automated Instruments (Incubators, Readers), Software & Data Management Systems, Testing Services), Test method / technology (Disk Diffusion (Kirby-Bauer), Broth Microdilution / Macrodilution, Agar Dilution, Gradient Diffusion (Etest), Automated Broth Microdilution Systems, Genotypic / Molecular AST, MALDI-TOF MS-Based AST), Organism type tested (Antibacterial Susceptibility Testing, Antifungal Susceptibility Testing, Antiviral Susceptibility Testing, Antiparasitic Susceptibility Testing), Application (Clinical Diagnostics, Drug Discovery & Antimicrobial Development, Epidemiological & AMR Surveillance, Food, Water & Environmental Testing, Veterinary & Animal Health Testing), Sample/specimen type (Blood & Blood Culture, Urine, Respiratory Specimens (Sputum/BAL), Wound, Tissue & Pus, Stool, Cerebrospinal & Other Sterile Body Fluids), End user (Hospital & Clinical Laboratories, Independent Reference & Commercial Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Public Health & Government Agencies), Testing site / care setting (Centralized/Reference Laboratory Testing, Point-of-Care & Near-Patient Testing, Decentralized On-Site Hospital Lab Testing), Distribution channel (Direct Sales, Third-Party Distributors, Group Purchasing Organizations (GPOs), Online/E-Procurement Platforms), Testing standard / breakpoint guideline (CLSI-Based Testing, EUCAST-Based Testing, Other National/Regional Standards), and Regional Forecast, 2026-2034". The study sizes the global antimicrobial susceptibility testing market at USD 4.65 billion in 2025 and projects growth from USD 5.04 billion in 2026 to USD 9.68 billion by 2034, a compound annual growth rate of 8.5% across the forecast period.
Antimicrobial susceptibility testing covers the instruments, reagents, consumables and software used to determine which antibiotics, antifungals, antivirals or antiparasitic agents will inhibit a specific pathogen isolated from a patient or environmental sample. It spans manual phenotypic methods such as disk diffusion and broth microdilution, automated instrument platforms, and genotypic methods that detect resistance genes directly, along with the data management systems that report results back into a laboratory or hospital record system. Buyers include hospital and reference clinical laboratories, public health and surveillance agencies, pharmaceutical and biotechnology developers testing new antimicrobial candidates, and food, water and veterinary testing laboratories.
Rising global antimicrobial resistance driving routine susceptibility testing volume
Rising global antimicrobial resistance driving routine susceptibility testing volume is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 8.5% a year, the product type lines exposed to it move fastest: Software & Data Management Systems compounds at 13.7%, taking its share of revenue from 4.7% to 8.1% and its value from USD 0.22 billion to USD 0.78 billion.
On the upside, the study's bull case assumes bull case assumes AMR surveillance mandates expand faster than currently legislated and automated or molecular platform adoption reaches mid-sized hospital laboratories a year or two ahead of the base case, which would take 2034 revenue to USD 10.84 billion against the USD 9.68 billion base case.
The downside is specific. Bear case assumes public health testing budgets tighten, slowing the replacement of manual methods and delaying planned national surveillance program expansions, and 2034 revenue lands at USD 8.52 billion. Reagents & Consumables is the drag, 38.1% of the 2025 base compounding at 7.9% while the market runs at 8.5%.
Key Players Compete on Reagents & Consumables Volume and Software & Data Management Systems Growth
Two positions matter, and they are set by product type. Reagents & Consumables carries 38.1% of 2025 revenue (USD 1.77 billion) and is still the largest line in 2034 at 36%, hard to take from an incumbent. Software & Data Management Systems, at 13.7%, is where the USD 4.65 billion base is redistributed. The two demand different capabilities.
Additional Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Test method / technology | Automated Broth Microdilution Systems | 24.1% · USD 1.12 billion | Genotypic / Molecular AST 12.9% |
| Organism type tested | Antibacterial Susceptibility Testing | 78.1% · USD 3.63 billion | Antifungal Susceptibility Testing 10.9% |
| Application | Clinical Diagnostics | 58.1% · USD 2.7 billion | Epidemiological & AMR Surveillance 11.6% |
| Sample/specimen type | Blood & Blood Culture | 32% · USD 1.49 billion | Cerebrospinal & Other Sterile Body Fluids 11.5% |
| End user | Hospital & Clinical Laboratories | 46% · USD 2.14 billion | Public Health & Government Agencies 11.8% |
| Testing site / care setting | Centralized/Reference Laboratory Testing | 54% · USD 2.51 billion | Point-of-Care & Near-Patient Testing 13.4% |
| Distribution channel | Direct Sales | 52% · USD 2.42 billion | Online/E-Procurement Platforms 17% |
| Testing standard / breakpoint guideline | CLSI-Based Testing | 54% · USD 2.51 billion | EUCAST-Based Testing 9.5% |
- North America was the largest region in 2025, holding 40.2% of global revenue at USD 1.87 billion and reaching USD 3.4 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 24.7% in 2025 to 31.8% in 2034, with revenue growing from USD 1.15 billion to USD 3.08 billion.
- Middle East and Africa remains the smallest region throughout, at 3.7% of 2025 revenue and 3.6% by 2034.
- By product type, the largest line in 2025 was Reagents & Consumables, at 38.1% of revenue and USD 1.77 billion.
- Software & Data Management Systems is projected to grow at 13.7% over the forecast period, the fastest of any product type line.
- The United States is the largest single country market at USD 1.62 billion in 2025, 34.8% of global revenue.
The report segments the market across nine axes; by product type, and by test method / technology, organism type tested, application, sample/specimen type, end user, testing site / care setting, distribution channel and testing standard / breakpoint guideline; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 8.52 billion and USD 10.84 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.